Effects of Combined Simultaneous and Sequential Endostar and Cisplatin Treatment in a Mice Model of Gastric Cancer Peritoneal Metastases

Abstract

Objective. Aimed to study the effects of endostar and cisplatin using an in vivo imaging system (IVIS) in a model of peritoneal metastasis of gastric cancer. Methods. NUGC-4 gastric cancer cells transfected with luciferase gene (NUGC-4-Luc) were injected i.p. into nude mice. One week later, mice were randomly injected i.p.: group 1, cisplatin (d1–3) + endostar (d4–7); group 2, endostar (d1–4) + cisplatin (d5–7); group 3, endostar + cisplatin d1, 4, and 7; group 4, saline for two weeks. One week after the final administration, mice were sacrificed. Bioluminescent data, microvessel density (MVD), and lymphatic vessel density (LVD) were analyzed. Results. Among the four groups, there were no significant differences in the weights and in the number of cancer cell photons on days 1 and 8 (P > 0.05). On day 15, the numbers in groups 3 and 1 were less than that in group 2 (P < 0.05). On day 21, group 3 was significantly less than group 2 (P < 0.05). MVD of group 4 was less than that of groups 1 and 2 (P < 0.01). There was no significant difference between groups 2 and 3 (P > 0.05) or in LVD number among the four groups (P > 0.05). Conclusions. IVIS® was more useful than weight, volume of ascites, and number of peritoneal nodules. The simultaneous group was superior to sequential groups in killing cancer cells and inhibiting vascular endothelium. Cisplatin-endostar was superior to endostar-cisplatin in killing cancer cells, while the latter in inhibiting peritoneal vascular endothelium.

LINC00052 Promotes Gastric Cancer Cell Proliferation and Metastasis via Activating the Wnt/β-Catenin Signaling Pathway

“…The occurrence of GC has definite connections with chronic gastritis, gastric polyps, and ulcers as well as dietary, environmental, and genetic factors 4–7 . Despite a number of chemotherapeutic compounds that have been used against this disease, the molecular mechanisms for occurrence and progression of GC remain unclear 8,9 . Therefore, more effort is still needed to reveal the mechanism of GC, which may be helpful for the development of GC treatment.…”

Peritoneal Metastatic Cancer Stem Cells of Gastric Cancer with Partial Mesenchymal-Epithelial Transition and Enhanced Invasiveness in an Intraperitoneal Transplantation Model

“…Previous studies have investigated the mechanism underlying peritoneal metastasis of GC in vitro [27,28]. Several models of peritoneal metastasis have been established by orthotopic implantation techniques and intraperitoneal injection of human GC cell lines [29][30][31][32][33]. We established a nude mouse model via intraperitoneal injection of CSC-hGC.…”

SPECT Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts in Vivo

“…As a recombinant human endostatin Endostar , was mainly used as an antiangiogenic agent for cancer treatment [3][4], which was approved by the China Food and Drug Administration (CFDA) in 2005 for treatment of lung cancer. Endostar exhibits antiangiogenic effects and has been used to treat numerous types of cancer, including non-small lung, breast, melanoma tumor, and gastric cancer [5][6][7][8][9][10]. Nevertheless, the bene ts of Endostar on pancreatic cancer are currently poorly known.…”